Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.52 |
| ▸ | GSK3A | P49840 | 19/20 | 0.52 |
| ▸ | CDK2 | P24941 | 4/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | MYLK | Q15746 | 1/20 | 0.44 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3263415 | 0.96 | GSK3B (0.49) | GSK3BGSK3ACDK2ADORA2AADORA1 | |
| SCHEMBL8043843 | 0.85 | GSK3A (0.58) | GSK3BGSK3ACDK2ADORA2AADORA1 | |
| SCHEMBL8043844 | 0.81 | GSK3A (0.54) | GSK3BGSK3ACDK2ADORA2AADORA1 | |
| SCHEMBL13099648 | 0.81 | FGFR1 (0.43) | GSK3BCDK2 | |
| SCHEMBL3265538 | 0.80 | GRM5 (0.43) | GSK3BCDK2 | |
| SCHEMBL3231677 | 0.79 | GSK3B (0.49) | GSK3BGSK3ACDK2ADORA2AADORA1 | |
| SCHEMBL8048684 | 0.70 | ROCK1 (0.46) | GSK3BGSK3A | |
| SCHEMBL8043054 | 0.69 | EPHB3 (0.47) | GSK3BGSK3A | |
| SCHEMBL13099726 | 0.69 | EGFR (0.39) | GSK3BGSK3ACDK2ADORA2AADORA1 | |
| SCHEMBL8031088 | 0.69 | CDK2 (0.41) | GSK3BGSK3ACDK2PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
| WO-2010027114-A1 | USE OF PYRAZOLE-PYRIDINE DERIVATIVES AND ITS SALTS FOR TREATING OR REVENTIN OSTEOPOROSIS | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009038385-A2 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | MAP3K20, MAP3K3, MAP3K1 | GSK3B 208/4885GSK3A 206/4885CDK2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.